Pathologic complete response (pCR) rates for patients with HR+/HER2− high-risk, early-stage breast cancer (EBC) by clinical and molecular features in the phase II I-SPY2 clinical trial

Laura A. Huppert, David S. Wolf, Christina Yau, Lamorna Brown Swigart, Gillian L. Hirst, Claudine Isaacs, Lajos Pusztai, Paula R. Pohlmann, Angela DeMichele, Rebecca Shatsky, Douglas Yee, Alexandra Thomas, Rita Nanda, Jane Perlmutter, Diane Heditsian, Nola M. Hylton, F Symmans, Laura J. van’t Veer, Laura J. Esserman, Hope S. Rugo